PetDx

PetDx is a San Diego-based biotechnology startup that focuses on improving pet health through genomics. Their flagship product, OncoK9, is a multi-cancer early detection (MCED) test that utilizes cutting-edge genomic analysis and next-generation sequencing (NGS) technology. This allows veterinarians to detect cancer in dogs with a simple blood draw, enabling superior care for canine patients.

Founded in 2019, PetDx recently secured a significant $62.00M Series B investment on 09 December 2021. The investment was led by Torch Capital, Valor Equity Partners, Aperture Venture Partners, Declaration Partners, LabCorp, Longview Asset Management, K4 Group, and Friedman BioVentures, showcasing the strong support and confidence from a diverse group of investors in the company's mission and potential.

With its innovative approach and substantial financial backing, PetDx is well-positioned to make a significant impact in the biotechnology space and revolutionize the way pet health is managed, making it an intriguing prospect for potential investors seeking opportunities in the rapidly evolving pet care industry.